Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study

• Jona T. Stahmeyer ,

  Contributed equally to this work with: Jona T. Stahmeyer, Siegbert Rossol

  * E-mail: Stahmeyer.Jona@mh-hannover.de

  Affiliation Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany

  ⨯
• Siegbert Rossol ,

  Contributed equally to this work with: Jona T. Stahmeyer, Siegbert Rossol

  Affiliation Department of Internal Medicine, Krankenhaus Nordwest, Frankfurt a.M., Germany

  ⨯
• Florian Bert,

  Affiliation Department of Internal Medicine, Krankenhaus Nordwest, Frankfurt a.M., Germany

  ⨯
• Klaus H. W. Böker,

  Affiliation Leberpraxis, Hannover, Germany

  ⨯
• Harald-Robert Bruch,

  Affiliation Schwerpunktpraxis Bonn, Bonn, Germany

  ⨯
• Christoph Eisenbach,

  Affiliation University Hospital Heidelberg, Dept. of Gastroenterology, Heidelberg, Germany

  ⨯
• Ralph Link,

  Affiliation St. Josefs Hospital, Offenburg, Germany

  ⨯
• Christine John,

  Affiliation Medical Practice, Berlin, Germany

  ⨯
• Stefan Mauss,

  Affiliation Center for HIV and Hepatogastroenterology, Duesseldorf, Germany

  ⨯
• Renate Heyne,

  Affiliation Leberzentrum am Checkpoint, Berlin, Germany

  ⨯
• Eckart Schott,

  Affiliation Dept. of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany

  ⨯
• Heike Pfeiffer-Vornkahl,

  Affiliation e-factum – GmbH, Butzbach, Germany

  ⨯
• Dietrich Hüppe,

  Affiliation Center of Gastroenterology, Herne, Germany

  ⨯
• Christian Krauth

  Affiliation Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany

  ⨯